Last reviewed · How we verify
NCT04861584
Neoadjuvant Toripalimab in Combination with Gemcitabine and Cisplatin Therapy in Local Advanced Bladder Cancer Subjects
Phase 2 trial testing Neoadjuvant Toripalimab in Combination With Gemcitabine and Cisplatin in Urinary Bladder Cancer in 41 participants. Currently enrolling.
3 October 2026
Quick facts
| Lead sponsor | Zhujiang Hospital |
|---|---|
| Phase | Phase 2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 41 |
| Start date | 3 June 2021 |
| Primary completion | 3 October 2026 |
| Estimated completion | 3 April 2027 |
| Sites | 1 location across China |
Drugs / interventions tested
- Neoadjuvant Toripalimab in Combination With Gemcitabine and Cisplatin — full drug profile →
Conditions studied
- Urinary Bladder Cancer — all drugs for Urinary Bladder Cancer →
Sponsor
Zhujiang Hospital
Who can join
Adults 18 to 75, any sex, with Urinary Bladder Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a pre-surgical study involving subjects with local advanced bladder cancer, who are candidates for neoadjuvant therapy. It is a single-arm phase II portion.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Neoadjuvant Treatment in Muscle-Invasive Bladder Cancer: From the Beginning to the Latest Developments.
Roviello G, Catalano M, Santi R, Santoni M, et al · · 2022 · cited 18× · PMID 35936721 · DOI 10.3389/fonc.2022.912699 -
Perioperative Systemic Treatment for Muscle-Invasive Bladder Cancer: Current Evidence and Future Perspectives.
Kim IH, Lee HJ. · · 2021 · cited 18× · PMID 34281253 · DOI 10.3390/ijms22137201 -
Neoadjuvant Immunotherapy in Bladder Cancer: Ushering in a New Era of Treatment-A Systematic Review of Current Evidence.
Suartz CV, de Lima RD, de Almeida LS, Liebl B, et al · · 2025 · cited 1× · PMID 40822997 · DOI 10.1016/j.euros.2025.07.010
Verify or expand the search:
- PubMed search for NCT04861584
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Urinary Bladder Cancer
Currently open trials in the same condition.
- NCT07165236 — Association of POCD With Circulating Biomarkers in Patients Undergoing TUR of Bladder Tumor · recruiting
- NCT05644041 — Intravesical Gem/Doce in Patients With NMIBC · Phase 2 · recruiting
- NCT05822934 — Carboplatin-gemcitabine Versus Cisplatin- Gemcitabine as Neoadjuvant Chemotherapy for Treatment of Muscle Invasive Urina · Phase 3 · active not recruiting
- NCT05621837 — Quantifying Systemic Immunosuppression to Personalize Cancer Therapy · recruiting
- NCT05072600 — Pembrolizumab Monotherapy Following Tri-modality Treatment for Selected Patients With Muscle-invasive Bladder Cancer · Phase 2 · recruiting
Other Zhujiang Hospital trials
Trials by the same sponsor.
- NCT07335094 — A Clinical Study of Humanized CD19 CAR-T Cells With TLR2 for the Treatment of Adult Patients With Naive B-Cell Acute Lym · EARLY_PHASE1 · not yet recruiting
- NCT07469072 — Comparison of Anticoagulant Effects of Different Doses of Nafamostat in Continuous Renal Replacement Therapy (CRRT) in t · Phase 2 · recruiting
- NCT07455149 — An Observational Clinical Study on the Association of Intestinal Ruminococcus Gnavus and Its Derived Biogenic Amines Wit · not yet recruiting
- NCT07457099 — Impact of Postoperative Radiotherapy Versus PD-1 Inhibitor Maintenance on Survival in Resectable Locally Advanced Oral a · not yet recruiting
- NCT07454421 — Racecadotril for Organ Injury in Sepsis Patients · Phase 1, PHASE2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04861584 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Zhujiang Hospital
- Last refreshed: 4 December 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04861584.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing